Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial

Liang Huang; Sheng Chen; Wentao Yang; Binghe Xu; Tao Huang; Hongjian Yang; Hong Zheng; Yongsheng Wang; Erwei Song; Jin Zhang; Shude Cui; Da Pang; Lili Tang; Yutao Lei; Cuizhi Geng; Zhiming Shao

doi:10.18632/oncotarget.4337

Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial

Oncotarget ◽

10.18632/oncotarget.4337 ◽

2015 ◽

Vol 6 (21) ◽

pp. 18683-18692 ◽

Cited By ~ 7

Author(s):

Liang Huang ◽

Sheng Chen ◽

Wentao Yang ◽

Binghe Xu ◽

Tao Huang ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Cancer Patients ◽

Clinical Stage ◽

Phase 2 ◽

Efficacy And Safety ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Positive Breast Cancer

Download Full-text

Abstract P4-12-17: Pathological responses and heart safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy in clinical stage II-III, HER2-positive breast cancer patients: A phase 2, open-label, multicentre, randomised trial

10.1158/0008-5472.sabcs13-p4-12-17 ◽

2013 ◽

Author(s):

L Huang ◽

S Chen ◽

W Yang ◽

B Xu ◽

T Huang ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Therapy ◽

Cancer Patients ◽

Clinical Stage ◽

Randomised Trial ◽

Phase 2 ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Positive Breast Cancer

Download Full-text

Phase 2 Study of a HER-2/neu Intracellular Domain Peptide-Based Vaccine Administered to Stage IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab

10.21236/ada538840 ◽

2010 ◽

Author(s):

Mary L. Disis

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Stage Iv ◽

Phase 2 ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Phase 2 Study ◽

Her 2 ◽

Domain Peptide ◽

Positive Breast Cancer

Download Full-text

Multicentric, open-label, single-arm phase II study with oral lapatinib in combination with oral capecitabine plus intrathecally administered liposomal cytarabine for the treatment of meningeal metastases (NM) in HER2-positive breast cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps123 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS123-TPS123

Author(s):

J. Bischoff

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Liposomal Cytarabine ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Oral Capecitabine ◽

Positive Breast Cancer

Download Full-text

PerTe: efficacy and safety of pertuzumab in “real life setting” for the neoadjuvant treatment of HER2-positive breast cancer patients

Annals of Oncology ◽

10.1093/annonc/mdx424.039 ◽

2017 ◽

Vol 28 ◽

pp. vi36

Author(s):

D. Cianniello ◽

A. Prudente ◽

R. Caputo ◽

M. Piezzo ◽

M. Riemma ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Neoadjuvant Treatment ◽

Real Life ◽

Efficacy And Safety ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Real Life Setting ◽

Positive Breast Cancer

Download Full-text

Study of HER-2/neu Intracellular Domain Peptide-Based Vaccine Administered to Stage IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab. Phase 2

10.21236/ada505213 ◽

2009 ◽

Author(s):

Mary L. Disis

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Stage Iv ◽

Phase 2 ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Her 2 ◽

Domain Peptide ◽

Positive Breast Cancer

Download Full-text

Abstract CT058: A phase 2 open-label study to evaluate the efficacy and safety of VT-464 in patients with androgen receptor positive triple-negative breast cancer patients, and men with ER positive breast cancer

10.1158/1538-7445.am2017-ct058 ◽

2017 ◽

Author(s):

Alexandra Zimmer ◽

Margaret E. Gatti-Mays ◽

Stan Lipkowitz ◽

Fatima Karzai ◽

James Gulley ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Phase 2 ◽

Efficacy And Safety ◽

Breast Cancer Patients ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Er Positive ◽

Positive Breast Cancer

Download Full-text

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(11)70336-9 ◽

2012 ◽

Vol 13 (1) ◽

pp. 25-32 ◽

Cited By ~ 1133

Author(s):

Luca Gianni ◽

Tadeusz Pienkowski ◽

Young-Hyuck Im ◽

Laslo Roman ◽

Ling-Ming Tseng ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Phase 2 ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Her2 Positive Breast Cancer ◽

Phase 2 Trial ◽

Open Label Phase ◽

Positive Breast Cancer

Download Full-text

Efficacy and safety of taxane plus anthracycline with or without cyclophosphamide in Chinese node-positive breast cancer patients: an open-label, randomized controlled trial

Breast Cancer Research and Treatment ◽

10.1007/s10549-019-05207-x ◽

2019 ◽

Vol 175 (3) ◽

pp. 659-666

Author(s):

Yan Lin ◽

Changjun Wang ◽

Xin Huang ◽

Xingtong Zhou ◽

Yidong Zhou ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Controlled Trial ◽

Cancer Patients ◽

Controlled Trial ◽

Efficacy And Safety ◽

Breast Cancer Patients ◽

Open Label ◽

Node Positive ◽

Randomized Controlled ◽

Positive Breast Cancer

Download Full-text

The efficacy and safety of pyrotinib in treating HER2‐positive breast cancer patients with brain metastasis: A multicenter study

Cancer Medicine ◽

10.1002/cam4.4481 ◽

2021 ◽

Author(s):

Min Gao ◽

Chao Fu ◽

Shanshan Li ◽

Fang Chen ◽

Yongteng Yang ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastasis ◽

Cancer Patients ◽

Multicenter Study ◽

Efficacy And Safety ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Positive Breast Cancer

Download Full-text

P3-14-13: A Prospective Open-Label Randomized Phase II Neoadjuvant Study of Non-Pegylated Liposomal Doxorubicin (MYOCET®) Plus Cyclophosphamide and Trastuzumab Versus Conventional Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in HER2−Positive Breast Cancer Patients.

10.1158/0008-5472.sabcs11-p3-14-13 ◽

2011 ◽

Cited By ~ 1

Author(s):

A Llombart-Cussac ◽

S Pernas-Simon ◽

M Rezai ◽

M Hauschild ◽

M Venturini ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Randomized Phase Ii ◽

Positive Breast Cancer

Download Full-text